JP Morgan Maintains Overweight on Ascendis Pharma, Lowers Price Target to $165
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowers the price target from $174 to $165.
September 04, 2024 | 10:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma but lowers the price target from $174 to $165, indicating a slightly less optimistic outlook.
The Overweight rating suggests continued confidence in Ascendis Pharma's potential, but the lowered price target reflects a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100